Application of Cystatin C in treating cerebral vasospasm after subarachnoid hemorrhage

Abstract

The invention discloses an application of Cystatin C in preparing a medicine composition used for treating cerebral vasospasm. Animal experiments prove that Cystatin C can induce high expression of autophagy on basilar artery walls, and has a controlling effect upon SD rat cerebral vasospasm after subarachnoid hemorrhage (SAH); and the effect has positive correlation with Cystatin C concentration. According to the invention, Cystatin C has substantial inhibiting effect against cerebral vasospasm after SAH, and can be used for ameliorating cerebral vasospasm after SAH.

Description

technical field [0001] The invention belongs to the technical field of new uses of medicines, and in particular relates to an application of Cystatin C in treating cerebral vasospasm after subarachnoid hemorrhage. Background technique [0002] The annual incidence of spontaneous subarachnoid hemorrhage (SAH) is about 6-16 / 100,000 people, accounting for about 6-8% of the total incidence of stroke. The rupture of intracranial aneurysms is the main cause of spontaneous SAH . Cerebral vasospasm (CVS) is a common and dangerous complication after subarachnoid hemorrhage (SAH), which can often cause severe brain ischemia or delayed ischemic brain damage, and even lead to Cerebral infarction is one of the main causes of death or disability. Studies have shown that after the onset of aneurysmal SAH, about 30%-70% of patients have vasospasm shown by angiography, and 20%-30% of patients have clinical symptoms. 32% to 67% have cerebral infarction, and 15% to 20% will eventually becom...

AI Technical Summary

Problems solved by technology

[0007] At present, the role of autophagy after SAH is mainly concentrated in the early brain injury, but whether Cystatin C has a preventive effect on intracranial vasospasm, there is no relevant literature report.

Images